IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
Sydney, Australia 21 November 2022 Highlights Clarity’s fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical…